n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, July 10th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Cantabio Pharmaceuticals, Inc. (CTBO)

Profitable Trader Authority, AwesomeStocks, HotStockProfits, ProfitableTrading, Investors Alley, Leebís Market Forecast, OTCtipReporter, and PennyStockScholar reported on Cantabio Pharmaceuticals, Inc. (CTBO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cantabio Pharmaceuticals, Inc. centers on bringing novel, first-in-class drug candidates into clinical trials and beyond. It does so through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders. These include Alzheimer’s, Parkinson’s, and oxidative stress. The Company is presently engaging in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. Cantabio Pharmaceuticals is headquartered in Sunnyvale, California.

A preclinical stage biotechnology company, Cantabio Pharmaceuticals, Inc. was established through the merger of Gardedam Therapeutics with Cantabio Pharmaceuticals in November 2015. It is concentrating on commercializing novel therapies and the Intellectual Property (IP) generated from its research and development (R&D) activities for Parkinson’s disease (PD), Alzheimer’s disease (AD), as well as other related neurodegenerative diseases.

The Company’s strategy mixes a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into a unique drug discovery approach. This approach is now identifying and developing small molecule pharmacological chaperones for clinical trials. Cantabio Pharmaceuticals is also developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins, which display loss of function during disease conditions.

Cantabio Pharmaceuticals has a new preclinical therapeutic program for Alzheimer’s disease that it is pursuing via its drug discovery partnership with NovAliX. The program is targeted at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a vital element in the onset and progression of Alzheimer’s disease.

Last week, Cantabio Pharmaceuticals announced a publication lead authored by the Company’s Chief Executive Officer, Dr. Gergely Toth, along with collaborators at the University of Cambridge, in the peer-reviewed journal ACS Chemical Neuroscience. The article is titled Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates using Microscale Thermophoresis. It reported on a novel and general methodology for studying small molecule and protein fibril interactions and demonstrated that one of Cantabio Pharmaceuticals’ lead Tau targeting pharmacological chaperone molecules binds to Tau fibrils with high affinity.

ACS Chemical Neuroscience publishes high-quality research articles and reviews. These showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders.

Cantabio Pharmaceuticals, Inc. (CTBO), closed Monday's trading session at $0.11, even for the day, on 34,505 volume with 11 trades. The average volume for the last 60 days is 7,105 and the stock's 52-week low/high is $0.082/$2.98.

Almadex Minerals Limited (AXDDF)

Streetwise Reports and MarketWatch reported on Almadex Minerals Limited (AXDDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Almadex Minerals Limited holds a large mineral portfolio consisting of projects and NSR royalties in the U.S., Canada, and Mexico. At present, the Company is focusing on exploration at its El Cobre gold/copper porphyry project in Veracruz, Mexico. Almadex Minerals is headquartered in Vancouver, British Columbia. An exploration enterprise, the Company’s shares trade on the OTCQB.

At its El Cobre gold/copper porphyry project, Almadex Minerals holds a 100 percent interest, subject to a sliding-scale Net Smelter Returns (NSR) royalty equivalent to 0.5 percent if production from the property exceeds 10,001 tonnes per day of ore. The NSR can be decreased to 0.25 percent at this production rate via the payment of US$3 million.

Company properties include the Merit Project, Nicoamen River, Ponderosa, and Skoonka Creek in the Southern British Columbia Gold Belt. In addition, the Company has its Lac de Gras area diamond project situated at Mackay Lake in the Northwest Territories. In Mexico, Almadex has its El Cobre Project; and a portfolio of Eastern Mexican projects at different stages of development.

In the U.S., Almadex has its Willow Project in Douglas and Lyon Counties, Nevada (about10,252 hectares). These 100 percent owned projects range from alteration zones that require target definition, through drill-ready projects.

Almadex Minerals acquired three Mexican properties from Alianza Minerals Ltd. It acquired the Yago, Mezquites, and San Pedro properties in return for a 1 percent NSR capped at CAD$1 million. Also, it sold its El Encuentro project to McEwen Mining, Inc.  for US$250,000 and a 2.0 percent NSR royalty.

Almadex Minerals earlier announced that it and its wholly-owned U.S. subsidiary, Almadex Americas, Inc. signed a definitive agreement to option up to 75 percent of its interest in the Willow project, Nevada, to Abacus Mining and Exploration Corp.

Recently, Almadex Minerals announced that it signed an agreement with Westhaven Ventures, Inc. and Strongbow Exploration Ltd.  Westhaven will acquire the Skoonka Creek gold property that is presently held by Strongbow and Almadex Minerals pursuant to a 65.74 percent/34.26 percent joint venture. In exchange for its interest in the Property, Almadex Minerals will receive, on closing of the transaction, 700,000 shares of Westhaven and a 2.0 percent Net Smelter Return (NSR) royalty on the Property.

In late June, Almadex Minerals announced that it received assay results from the top of hole EC-17-025 that was collared into a newly recognized area of exposed stockwork quartz veining and gold mineralization in the Encinal Zone of the project. The Encinal Zone is approximately 3.5 kilometers to the south-southeast of the Norte Zone drilling and 2.5 kilometers southeast of the recently identified Raya Tembrillo Zone of stockwork veining. So far, assays have been received to a depth 300.36 meters with assays pending for the remainder of the hole. Significant mineralization was intersected from the collar.

J. Duane Poliquin, Chairman of Almadex Minerals, said, "While we are carrying out a systematic drill campaign to follow-up results in the Norte zone, there are other significant porphyry occurrences on the project that require drill testing most notably the newly identified Raya Tembrillo target.”

Almadex Minerals Limited (AXDDF), closed Monday's trading session at $0.7578, up 4.51%, on 29,603 volume with 30 trades. The average volume for the last 60 days is 37,580 and the stock's 52-week low/high is $0.3082/$1.51.

Butler National Corp. (BUKS)

Zacks, Marketbeat, MarketWatch, and FeedBlitz reported on Butler National Corp. (BUKS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Butler National Corp. is a top manufacturer and provider of support systems for commercial and military aircraft. Additionally, the Company is a recognized provider of management services in diverse business groups. These include the gaming industry. Butler operates in the Aerospace/Defense Products & Services industry in the Industrial Goods sector.

The Company is based in Olathe, Kansas. Butler National Corporation established in 1968 through the merger of an aviation research firm owned by the Butler family and National Connector Corporation. Butler National combined resources of the two companies to develop one of the first commercial Area Navigation System (RNAV) used for airplane navigation.

The Company’s subsidiaries include Avcon Industries, Inc.; Butler Avionics, Inc.; BCS Design, Inc.; Boot Hill Casino & Resort; The Stables Casino; and Butler National-Tempe. Avcon Industries provides aircraft owners and operators with products and services designed to satisfy special mission requirements, or enhance the utility of business jets and turboprops.

Butler National’s Aerospace segment centers on the manufacturing of support systems for "Classic" commercial and military aircraft. This includes the Butler National TSD for the Boeing 737 and 747 Classic aircraft.

In addition, this segment concentrates on switching equipment for Boeing McDonnell Douglas Aircraft, weapon control systems for Boeing Helicopter, and performance enhancement structural modifications for Learjet, Cessna, Dassault, and Beechcraft business aircraft. The Company’s Management Services segment includes temporary employee services, gaming services, and administrative management services.

Butler Avionics’ services include new installations and retrofits, to avionics, autopilot, instruments, and radar troubleshooting and repair. BCS Design is a full-service architectural firm.

Boot Hill Casino & Resort is in Dodge City, Kansas. It is home to the first state owned and operated casino gaming in Kansas. The Stables Casino is a Class III gaming establishment in Miami, Oklahoma. It is owned by the Miami Tribe and the Modoc Tribe. Butler National-Tempe operates in the Defense Contracting & Electronics industry.

This past April, Butler National announced Federal Aviation Administration (FAA) Supplemental Type Certificate issuance and Parts Manufacturing Approval of a new vertical accelerometer for Learjet airplanes. The Company (incorporating new technologies) designed, manufactured, and also obtained FAA Supplemental Type Certificate (STC) approval of a replacement vertical accelerometer for use by the autopilot on the applicable Learjet Model 31/35/35A/36/36A/C-21A and 55 Series airplanes. The replacement accelerometer is approved for installation under STC number ST02515SE.

Mr. Clark D. Stewart, President and Chief Executive Officer of Butler National, said in April, “We are pleased to continue offering new components and system upgrades for sale to operators of legacy Learjets.  We believe the new replacement vertical accelerometer, the AV-500B Mod A, will offer enhanced reliability and improved performance for the applicable Learjets.”

Butler National Corp. (BUKS), closed Monday's trading session at $0.3202, down 9.16%, on 44,022 volume with 16 trades. The average volume for the last 60 days is 60,316 and the stock's 52-week low/high is $0.1551/$0.4799.

Emergent Capital, Inc. (EMGC)

OTC Markets, MarketWatch, and 4-Traders reported on Emergent Capital, Inc. (EMGC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Emergent Capital, Inc. is a specialty finance company. It invests in life settlements and is a global leader in the life settlements industry. Emergent Capital has decades of experience creating value by way of the secondary and tertiary markets for life insurance policies.

Emergent Capital is based in Boca Raton, Florida. The Company formed in 2006 as Imperial Holdings, LLC. Since 2011 it has been publicly traded. In 2015, shareholders voted to change the Company’s name to Emergent Capital, Inc.

Regarding Life settlements, they are an alternative asset class that can provide high uncorrelated returns. Emergent Capital has access to a wide-ranging and proven network of life settlement brokers and third-party providers from whom it sources appealing and value-added policies.

In essence, the Company purchases individual policies and portfolios of life insurance policies. It manages these assets based on comprehensive actuarial and market data.
Moreover, an Emergent Capital subsidiary can act as a life settlement provider in more than 30 states where it is able to pursue numerous opportunities within the life settlement space.

Emergent Capital’s aim is to produce a consistent flow of investment opportunities covering all facets of the life settlements marketplace. These range from lending to outright purchases of portfolios, to tertiary trades, as well as individual secondary market purchases.

The Company’s Senior Executive team and staff represent greater than seven decades in the financial markets. Mr. Antony Mitchell is Chief Executive Officer (CEO) & Director of Emergent Capital. Mr. Mitchell has served as the CEO of Imperial Holdings since its establishment in February of 2007, and before August 14, 2012, also served as its Chairman. He has more than 25 years of experience in the financial industry.

For investor consideration, life settlements have limited correlation to the stock market or the larger economic market. They can serve as a hedge against the volatility of more market-dependent investments. In addition, life settlements represent a compelling and diversified investment opportunity to include longevity risk in a portfolio.

Emergent Capital, Inc. (EMGC), closed Monday's trading session at $0.28, down 8.20%, on 349,575 volume with 19 trades. The average volume for the last 60 days is 102,084 and the stock's 52-week low/high is $0.189/$0.35.

Creative Realities, Inc. (CREX)

MarketWatch and Wall Street Journal reported on Creative Realities, Inc. (CREX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Creative Realities, Inc. is a leading provider of digital marketing solutions. The Company helps retailers and brands utilize the most contemporary technologies to inspire shopper engagement in and around the Store. Creative Realities provides digital marketing technology solutions to retailers, brand marketers, venue-operators, enterprises, and non-profits and other organizations in the United States and internationally.

The Company has created and delivered consumer/shopper experiences. Creative Realities designs and installs high-end audio-visual networks. Furthermore, it is actively providing recurring SaaS (Software as a Service) and support services across wide-ranging categories. These categories include Automotive, Apparel & Accessories, Banking, Baby/Children, Beauty, CPG, Department Stores, Digital Out-of-Home (DOOH), Electronics, Fashion, Fitness, Foodservice/QSR, Financial Services, Gaming, Luxury, Mass Merchants, Mobile Operators, and Pharmacy Retail.

Pertaining to Customer Service, Creative Realities hosts, monitors, and also provides technical support to thousands of inventive deployments each day. This is through the Company’s Network Operation Center and Technical Services Team. Regarding Engineering, the Company provides complete systems engineering from blueprints to on-site programming and continuing systems management.

Concerning Content Management products and delivery, Creative Realities designs, curates, traffics, and delivers any type of content via best in class CMS software solutions, tailored to the schedule requirements for a single or multi-site network. Since the Company’s inception, it has successfully installed more than 100,000 retail and out of home experiences.

In late June, Creative Realities announced that a wholly-owned subsidiary of the Company was awarded purchase orders totaling $6.2 million under an existing Master Services Agreement with a foremost Mobile Network Operator (MNO). The MNO has been a client since 2012.

With these purchase orders, Creative Realities will provide software and services related to certain of the MNO's systems. The expectation is that Revenues from these purchases will be recognized in the second, third and fourth calendar quarters of 2017.

Creative Realities, Inc. (CREX), closed Monday's trading session at $0.36, even for the day, on 15,519 volume with 5 trades. The average volume for the last 60 days is 17,828 and the stock's 52-week low/high is $0.101/$0.45.

graphic

The QualityStocks
Company Corner

graphic
graphic

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.46, up 10.84%, on 54,255 volume with 23 trades. The stock’s average daily volume over the past 60 days is 60,236 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. today announces the availability of a Microsoft publication highlighting the Company's surgical resource management (SRM) solution in use at the nationally recognized Hoag Orthopedic Institute (HOI) in Irvine, California. The case study, entitled "Orthopedic hospital tests cloud-based cure for symptoms of rising healthcare costs," discusses HOI's experience using ORHub's software as an actionable resource analytics tool for its spinal surgeries. To view the full publication, visit: https://customers.microsoft.com/en-us/story/hoi-health-azure

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

Microsoft Publication Demonstrates Vital Capabilities of ORHub, Inc.'s Surgical Resource Management Solution

ORHub, Inc. Continues Market Expansion with New Customer-Requested Specialty Modules

ORHub (ORHB) Sets Exercise Price for its Series B and D Warrants

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.255, up 0.99%, on 206,247 volume with 123 trades. The stock’s average daily volume over the past 60 days is 595,893, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce it has entered into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Signs R&D Agreement with ATERA

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media

InMed Announces Agreement to Advance a Topical Formulation of INM-750

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $0.85, off by 4.49%, on 46,620 volume with 26 trades. The stock’s average daily volume over the past 60 days is 53,420 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com, the premier financial information website for Chinese-speaking investors, today announces that its wholly-owned subsidiary, Chinesehempoil.com Inc., will officially accept Bitcoin payments. Consumers who buy hemp-based health products, foods, and beverages can use Bitcoins in addition to more common payment methods, such as debit cards or PayPal.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com, Inc. Announces its Wholly-owned Subsidiary, Chinesehempoil.com Inc., Will Officially Accept Bitcoin Payments

CFN Media Interviews ChineseInvestors.com CEO Warren Wang

ChineseInvestors.com, Inc.'s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp Infused Skin Care Line in China

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0195, off by 2.01%, on 7,687,001 volume with 278 trades. The stock’s average daily volume over the past 60 days is 6,546,145, and its 52-week low/high is $0.0075/$0.142.

Singlepoint, Inc. the leading creative agency and media network dedicated to legal cannabis, announces publication of an article that will take a look at SinglePoint Inc.'s (OTC PINK: SING) recent agreement with Premier Biomedical Inc. to begin manufacturing Premier's newly designed CBD Hemp Oil Patch products in high volume.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Signs Deal to Manufacture CBD Hemp Oil Patches -- CFN Media

Premier Biomedical Launches Volume Manufacture of Topical Pain Relief Products Enabling Significant Expansion of Business

SinglePoint Secures Funding to Bring BitCoin to Cannabis -- CFN Media

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.491, even with yesterday's close. The stock’s average daily volume over the past 60 days is 3,178, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp., an education technology (EdTech) company building the first full-service training, compliance and career advancement brand for the skilled trades, today announced that it has retained PCG Advisory Group, a leading integrated communications firm, to serve as an advisor for investor relations and social media communications strategies.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Selects PCG Advisory Group for Investor Relations and Strategic Communications

ProBility Media Corp. Closes the Acquisition of W Marketing

ProBility Media Corp. Reports Fourth Consecutive Quarter of Revenue Growth

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

ProTrader
(PLLX) +355.51%

2.

StockHideout
(BWTX) +122.00%

3.

Penny Picks
(HIHI) +55.94%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251